Cite
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
MLA
Jeon, Changwan, et al. “Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.” Oncology, vol. 102, no. 6, June 2024, pp. 465–75. EBSCOhost, https://doi.org/10.1159/000534626.
APA
Jeon, C., Kang, S. H., Kim, S.-B., Paik, N.-S., Lee, I., Kim, S. K., Kim, E. Y., Son, G. S., Yoo, Y. B., Lee, K.-H., Shin, J., Ju, S., Jang, H., & Park, M. H. (2024). Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study. Oncology, 102(6), 465–475. https://doi.org/10.1159/000534626
Chicago
Jeon, Changwan, Su Hwan Kang, Sung-Bae Kim, Nam-Sun Paik, Ilkyun Lee, Seung Ki Kim, Eun Young Kim, et al. 2024. “Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.” Oncology 102 (6): 465–75. doi:10.1159/000534626.